{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["6(8)"],"submitter":["Liu H"],"funding":["Merck &amp; Co Inc","Pfizer Canada Inc"],"pubmed_abstract":["<h4>Introduction</h4>Sodium-glucose cotransporter-2 (SGLT2) inhibitors improve cardiovascular and kidney outcomes through mechanisms that are incompletely understood. In this exploratory post-hoc analysis of the VERTIS RENAL trial, we report the association between the SGLT2 inhibitor, ertugliflozin, and markers of kidney injury, inflammation, and fibrosis in participants with type 2 diabetes (T2D) and stage 3 chronic kidney disease (CKD).<h4>Methods</h4>Participants were randomized to ertugliflozin (5 or 15 mg/d) or placebo, and plasma samples for biomarker analysis were collected at baseline, 26 weeks, and 52 weeks.<h4>Results</h4>Ertugliflozin-treated participants had lower plasma levels of kidney injury molecule-1 (KIM-1) at 26 weeks (<i>P</i> = 0.044) and 52 weeks (<i>P</i> = 0.007) a"],"journal":["Kidney international reports"],"pagination":["2095-2104"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8343791"],"repository":["biostudies-literature"],"pubmed_title":["Markers of Kidney Injury, Inflammation, and Fibrosis Associated With Ertugliflozin in Patients With CKD and Diabetes."],"pmcid":["PMC8343791"],"pubmed_authors":["Liu H","Burger D","Burns K","Cherney DZI","Sridhar VS","Lytvyn Y","Brinc D","Lawler PR","Lovblom LE"],"additional_accession":[]},"is_claimable":false,"name":"Markers of Kidney Injury, Inflammation, and Fibrosis Associated With Ertugliflozin in Patients With CKD and Diabetes.","description":"<h4>Introduction</h4>Sodium-glucose cotransporter-2 (SGLT2) inhibitors improve cardiovascular and kidney outcomes through mechanisms that are incompletely understood. In this exploratory post-hoc analysis of the VERTIS RENAL trial, we report the association between the SGLT2 inhibitor, ertugliflozin, and markers of kidney injury, inflammation, and fibrosis in participants with type 2 diabetes (T2D) and stage 3 chronic kidney disease (CKD).<h4>Methods</h4>Participants were randomized to ertugliflozin (5 or 15 mg/d) or placebo, and plasma samples for biomarker analysis were collected at baseline, 26 weeks, and 52 weeks.<h4>Results</h4>Ertugliflozin-treated participants had lower plasma levels of kidney injury molecule-1 (KIM-1) at 26 weeks (<i>P</i> = 0.044) and 52 weeks (<i>P</i> = 0.007) a","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Aug","modification":"2026-05-08T20:56:10.935Z","creation":"2022-02-11T07:26:43.128Z"},"accession":"S-EPMC8343791","cross_references":{"pubmed":["34386658"],"doi":["10.1016/j.ekir.2021.05.022"]}}